Literature DB >> 10588700

Modification of EWS/WT1 functional properties by phosphorylation.

J Kim1, J M Lee, P E Branton, J Pelletier.   

Abstract

In many human cancers, tumor-specific chromosomal rearrangements are known to create chimeric products with the ability to transform cells. The EWS/WT1 protein is such a fusion product, resulting from a t(11;22) chromosomal translocation in desmoplastic small round cell tumors, where 265 aa from the EWS amino terminus are fused to the DNA binding domain of the WT1 tumor suppressor gene. Herein, we find that EWS/WT1 is phosphorylated in vivo on serine and tyrosine residues and that this affects DNA binding and homodimerization. We also show that EWS/WT1 can interact with, and is a substrate for, modification on tyrosine residues by c-Abl. Tyrosine phosphorylation of EWS/WT1 by c-Abl negatively regulates its DNA binding properties. These results indicate that the biological activity of EWS/WT1 is closely linked to its phosphorylation status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588700      PMCID: PMC24431          DOI: 10.1073/pnas.96.25.14300

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  The WT1 Wilms' tumor suppressor gene: how much do we really know?

Authors:  J C Reddy; J D Licht
Journal:  Biochim Biophys Acta       Date:  1996-05-16

2.  Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II.

Authors:  R Petermann; B M Mossier; D N Aryee; V Khazak; E A Golemis; H Kovar
Journal:  Oncogene       Date:  1998-08-06       Impact factor: 9.867

3.  In situ detection of sequence-specific DNA binding activity specified by a recombinant bacteriophage.

Authors:  C R Vinson; K L LaMarco; P F Johnson; W H Landschulz; S L McKnight
Journal:  Genes Dev       Date:  1988-07       Impact factor: 11.361

4.  Structural changes in glycogen phosphorylase induced by phosphorylation.

Authors:  S R Sprang; K R Acharya; E J Goldsmith; D I Stuart; K Varvill; R J Fletterick; N B Madsen; L N Johnson
Journal:  Nature       Date:  1988-11-17       Impact factor: 49.962

5.  Regulation of an enzyme by phosphorylation at the active site.

Authors:  J H Hurley; A M Dean; J L Sohl; D E Koshland; R M Stroud
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

6.  Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation.

Authors:  B Lüscher; E Christenson; D W Litchfield; E G Krebs; R N Eisenman
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

7.  The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein.

Authors:  E Karnieli; H Werner; F J Rauscher; L E Benjamin; D LeRoith
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

8.  Novel oncogenic mutations in the WT1 Wilms' tumor suppressor gene: a t(11;22) fuses the Ewing's sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor.

Authors:  F J Rauscher; L E Benjamin; W J Fredericks; J F Morris
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Proline-rich sequences that bind to Src homology 3 domains with individual specificities.

Authors:  K Alexandropoulos; G Cheng; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more
  10 in total

Review 1.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

2.  A transcription assay for EWS oncoproteins in Xenopus oocytes.

Authors:  King Pan Ng; Felix Cheung; Kevin A W Lee
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

3.  Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.

Authors:  Vittorio Caropreso; Emad Darvishi; Thomas J Turbyville; Ranjala Ratnayake; Patrick J Grohar; James B McMahon; Girma M Woldemichael
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

4.  Regulation of oncogenic transcription factor hTAF(II)68-TEC activity by human glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Authors:  Sol Kim; Jungwoon Lee; Jungho Kim
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

5.  Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in response to DNA damage.

Authors:  Tianzhuo Zhang; Zhe Wang; Minghui Liu; Lu Liu; Xin Yang; Yu Zhang; Juntao Bie; Yutong Li; Mengmeng Ren; Chen Song; Wengong Wang; Hongyu Tan; Jianyuan Luo
Journal:  Oncogene       Date:  2022-06-22       Impact factor: 8.756

6.  The EWS-Oct-4 fusion gene encodes a transforming gene.

Authors:  Jungwoon Lee; Ja Young Kim; In Young Kang; Hye Kyoung Kim; Yong-Mahn Han; Jungho Kim
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

7.  O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma.

Authors:  R Bachmaier; D N T Aryee; G Jug; M Kauer; M Kreppel; K A Lee; H Kovar
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

8.  Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins.

Authors:  King Pan Ng; Gary Potikyan; Rupert O V Savene; Christopher T Denny; Vladimir N Uversky; Kevin A W Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

Review 9.  Structure-function based molecular relationships in Ewing's sarcoma.

Authors:  Roumiana Todorova
Journal:  Biomed Res Int       Date:  2015-01-22       Impact factor: 3.411

10.  Polycation-π interactions are a driving force for molecular recognition by an intrinsically disordered oncoprotein family.

Authors:  Jianhui Song; Sheung Chun Ng; Peter Tompa; Kevin A W Lee; Hue Sun Chan
Journal:  PLoS Comput Biol       Date:  2013-09-26       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.